Jean-Charles Soria/LinkedIn
Mar 24, 2025, 10:50
Jean-Charles Soria: KRAS remained one of the most challenging targets in cancer research
Jean-Charles Soria, Head of Oncology Therapeutic Area at Amgen, posted on LinkedIn:
“For years, KRAS remained one of the most challenging targets in cancer research. In fact, many believed it was impossible to target.
Amgen scientists are relentless about pushing the boundaries of science. They pioneered game-changing research into KRAS G12C, a mutation that drives cancer growth for some patients with tough-to-treat cancers like NSCLC and mCRC.
Now, with two FDA-approved treatments targeting KRAS G12C, My Company continues to explore new frontiers to bring hope to patients.
Learn more at FindKRASG12C.com.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 24, 2025, 12:15
Mar 24, 2025, 12:14
Mar 24, 2025, 11:50
Mar 24, 2025, 11:39